Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. November 2021 05:55 ET | Quelle: Novan, Inc.

Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results

– Company executing on plans for three potential New Drug Application (NDA) filings in three years with the first submission targeted in Q3 2022 for lead program SB206 in molluscum contagiosum – –...
09. November 2021 08:35 ET | Quelle: Novan, Inc.

Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for Treatment of COVID-19

– Data indicate that intranasal administration of SB019 formulation containing berdazimer sodium is well-tolerated and safe under the conditions of preclinical study – – Company believes the...
03. November 2021 09:00 ET | Quelle: Novan, Inc.

Novan to Report Third Quarter 2021 Financial Results on November 10, 2021

DURHAM, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2021 financial results on Wednesday,...
10. Juni 2021 08:30 ET | Quelle: Novan, Inc.

Novan Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program

– Data indicate that berdazimer sodium prevents progression of SARS-CoV-2 infection in two independent in vivo transmission studies – – Statistically significant, dose-dependent reduction in the...
11. Mai 2021 16:05 ET | Quelle: Novan, Inc.

Novan Reports First Quarter 2021 Financial Results and Provides Corporate Update

– Topline efficacy results for ongoing Phase 3 study evaluating SB206 as a treatment for molluscum on track for targeted readout before the end of Q2 2021 – – Preclinical program underway evaluating...